Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
SAN DIEGO , March 8, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
- Etrasimod demonstrated clinical response and durable, long-term clinical remission and favorable long-term safety and tolerability in an open-label extension trial - Completed global license agreement with United Therapeutics for ralinepag, received $800M upfront payment, and eligible to receive
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019
View HTML
Toggle Summary Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26
SAN DIEGO , Feb. 20, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live webcast to
View HTML
Toggle Summary Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB 2 ) in
View HTML
Toggle Summary Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
SAN DIEGO , Jan. 24, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral,
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
- Etrasimod demonstrated clinical response and durable, long-term clinical remission - Etrasimod demonstrated favorable long-term safety and tolerability SAN DIEGO , Jan. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from the open-label extension
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO , Dec. 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 8:30
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
SAN DIEGO , Dec. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience in the life sciences industry.
View HTML
Toggle Summary Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs
SAN DIEGO , Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointments of Robert Lisicki as Executive Vice President and Chief Commercial Officer, and Paul K. Audhya , MD, MBA, as Senior Vice President, Medical Affairs. Mr.
View HTML